Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Tricida (TCDA) Plummets on Regulatory Update on Veverimer

Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).

Celsion Down on DMC Recommendation to Stop Liver Cancer Study

Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.

Horizon Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Horizon Therapeutics Public.

Is Horizon Therapeutics (HZNP) Stock a Solid Choice Right Now?

Horizon Therapeutics (HZNP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Is Horizon Therapeutics (HZNP) Up 13.2% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Horizon Therapeutics (HZNP) Surpasses Q1 Earnings and Revenue Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 91.30% and 25.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More

Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Hanger (HNGR) to Report Q1 Earnings: What's in the Cards?

Hanger's (HNGR) first-quarter 2020 results are likely to reflect strong performance at its Patient Care segment, partially offset by high costs.

Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Horizon Therapeutics (HZNP) Down 16.6% Since Last Earnings Report: Can It Rebound?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 30.23% and 3.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates

It was a low-key week for the biotech sector with updates from just a few small biotech companies.

Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.

Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

REGN vs. HZNP: Which Stock Is the Better Value Option?

REGN vs. HZNP: Which Stock Is the Better Value Option?

Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza

Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.

Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon

A low-key week for the biotech sector with a few pipeline and regulatory updates.

Horizon Therapeutics' Stock Up in a Year on Pipeline Progress

Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.

ALXN vs. HZNP: Which Stock Should Value Investors Buy Now?

ALXN vs. HZNP: Which Stock Is the Better Value Option?